• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GBIO

    Generation Bio Co.

    Subscribe to $GBIO
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: generationbio.com

    Peers

    $BXRX
    $GOSS
    $GRTS
    $PASG
    $PRVB
    $SESN
    $TIL
    $GRPH

    Recent Analyst Ratings for Generation Bio Co.

    DatePrice TargetRatingAnalyst
    10/19/2023Outperform → Market Perform
    TD Cowen
    11/8/2022$9.00Buy
    Canaccord Genuity
    12/15/2021$40.00 → $10.00Market Outperform
    JMP Securities
    12/15/2021$50.00 → $27.00Buy
    Needham
    12/14/2021Outperform → Mkt Perform
    William Blair
    See more ratings

    Generation Bio Co. SEC Filings

    See more
    • SEC Form S-8 filed by Generation Bio Co.

      S-8 - Generation Bio Co. (0001733294) (Filer)

      5/7/25 4:21:11 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Generation Bio Co.

      10-Q - Generation Bio Co. (0001733294) (Filer)

      5/7/25 4:15:25 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Generation Bio Co. (0001733294) (Filer)

      5/7/25 4:10:12 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Generation Bio Co.

      DEFA14A - Generation Bio Co. (0001733294) (Filer)

      4/23/25 4:11:43 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Generation Bio Co.

      DEF 14A - Generation Bio Co. (0001733294) (Filer)

      4/23/25 4:06:56 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Generation Bio Co.

      10-K - Generation Bio Co. (0001733294) (Filer)

      3/13/25 4:15:45 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Generation Bio Co. (0001733294) (Filer)

      3/13/25 4:10:10 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Co. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Generation Bio Co. (0001733294) (Filer)

      2/28/25 4:53:32 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Generation Bio Co.

      SCHEDULE 13G/A - Generation Bio Co. (0001733294) (Subject)

      2/12/25 9:28:11 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Co. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Generation Bio Co. (0001733294) (Filer)

      1/6/25 4:45:15 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Generation Bio Co. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF SCIENTIFIC OFFICER Samayoa Phillip converted options into 1,147 shares and covered exercise/tax liability with 337 shares, increasing direct ownership by 0.63% to 128,519 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      4/17/25 4:05:20 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Mcdonough Geoff covered exercise/tax liability with 1,548 shares and converted options into 5,274 shares, increasing direct ownership by 0.28% to 1,349,664 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      4/17/25 4:05:18 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF OPERATING OFFICER Paone Antoinette converted options into 1,592 shares and covered exercise/tax liability with 468 shares, increasing direct ownership by 5% to 23,082 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      4/17/25 4:05:13 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF LEGAL OFFICER Howze Yalonda converted options into 3,347 shares and covered exercise/tax liability with 983 shares, increasing direct ownership by 14% to 18,737 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      4/17/25 4:05:10 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Conway Kevin John converted options into 587 shares and covered exercise/tax liability with 173 shares, increasing direct ownership by 2% to 17,859 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      4/17/25 4:05:06 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Conway Kevin John converted options into 587 shares and covered exercise/tax liability with 204 shares, increasing direct ownership by 2% to 17,445 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      1/17/25 4:05:14 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF SCIENTIFIC OFFICER Samayoa Phillip converted options into 1,147 shares and covered exercise/tax liability with 398 shares, increasing direct ownership by 0.59% to 127,709 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      1/17/25 4:05:11 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF LEGAL OFFICER Howze Yalonda converted options into 3,347 shares and covered exercise/tax liability with 1,160 shares, increasing direct ownership by 15% to 16,373 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      1/17/25 4:05:12 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Mcdonough Geoff covered exercise/tax liability with 1,828 shares and converted options into 5,274 shares, increasing direct ownership by 0.26% to 1,345,938 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      1/17/25 4:05:06 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF OPERATING OFFICER Paone Antoinette converted options into 1,592 shares and covered exercise/tax liability with 552 shares, increasing direct ownership by 5% to 21,958 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      1/17/25 4:05:09 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Generation Bio Co. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Quinn Anthony G. bought $203,209 worth of shares (210,791 units at $0.96), increasing direct ownership by 238% to 299,286 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      1/14/25 4:05:17 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Appelhans Dannielle bought $14,339 worth of shares (8,000 units at $1.79), increasing direct ownership by 5% to 12,637 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      12/11/23 4:30:19 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Appelhans Dannielle bought $18,000 worth of shares (12,000 units at $1.50) (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      12/6/23 4:30:13 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quinn Anthony G. bought $124,778 worth of shares (88,495 units at $1.41) (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      12/5/23 4:30:36 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nicholson Donald William bought $144,000 worth of shares (100,000 units at $1.44), increasing direct ownership by 88% to 213,576 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      12/5/23 4:30:20 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rowland Charles A Jr bought $477,778 worth of shares (342,960 units at $1.39), increasing direct ownership by 179% to 534,757 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      12/5/23 4:30:27 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Generation Bio Co. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      12/9/24 6:18:02 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      11/14/24 1:22:38 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      2/14/24 10:03:03 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      2/13/24 6:17:56 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      2/9/24 4:05:55 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      2/9/24 9:03:02 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      1/8/24 4:35:41 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      12/11/23 9:09:53 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Generation Bio Co.

      SC 13G - Generation Bio Co. (0001733294) (Subject)

      3/24/23 4:27:53 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      2/14/23 4:18:59 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Generation Bio Co. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    Generation Bio Co. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Generation Bio downgraded by TD Cowen

      TD Cowen downgraded Generation Bio from Outperform to Market Perform

      10/19/23 7:43:32 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Generation Bio with a new price target

      Canaccord Genuity initiated coverage of Generation Bio with a rating of Buy and set a new price target of $9.00

      11/8/22 6:17:49 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Generation Bio with a new price target

      JMP Securities reiterated coverage of Generation Bio with a rating of Market Outperform and set a new price target of $10.00 from $40.00 previously

      12/15/21 7:17:06 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Generation Bio with a new price target

      Needham reiterated coverage of Generation Bio with a rating of Buy and set a new price target of $27.00 from $50.00 previously

      12/15/21 6:40:48 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio downgraded by William Blair

      William Blair downgraded Generation Bio from Outperform to Mkt Perform

      12/14/21 11:03:53 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Generation Bio with a new price target

      JMP Securities initiated coverage of Generation Bio with a rating of Mkt Outperform and set a new price target of $40.00

      6/8/21 7:08:47 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Generation Bio with a new price target

      William Blair initiated coverage of Generation Bio with a rating of Outperform and set a new price target of $45.00

      3/1/21 8:36:10 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham & Company LLC initiated coverage on Generation Bio with a new price target

      Needham & Company LLC initiated coverage of Generation Bio with a rating of Buy and set a new price target of $50.00

      2/25/21 10:47:18 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Generation Bio

      William Blair initiated coverage of Generation Bio with a rating of Outperform

      2/24/21 6:27:46 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Generation Bio with a new price target

      William Blair initiated coverage of Generation Bio with a rating of Outperform and set a new price target of $45.00

      2/24/21 6:04:34 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

      -  Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA -  Lead target and portfolio strategy to be announced mid-2025 -  Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and first quarter 2025 financial results."Our selective, redosable cell-targeted lipid nanoparticle (ctLNP) delivery syste

      5/7/25 4:05:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

      CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event.   About Generation Bio Generation Bio is a biotechnology company working to chan

      4/2/25 6:59:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

      -  Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases -  Lead target and indication to be announced MY 2025 -  Cash balance of $185.2 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., March 13, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and fourth quarter and full year 2024 financial results. "Our T cell-selective lipid nanoparticle (LNP) is designed to overcome a

      3/13/25 4:05:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference

      CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event.   About Generation Bio    Generation Bio is a biotechnology company changing what's possible for peo

      2/24/25 6:59:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

      Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it

      2/6/25 5:00:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases

      Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivoPrograms to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseasesCompany reorganization supports evolution of ctLNP-enabled strategy and buildout of clinical capabilities ahead of first IND expected in 2H 2026 CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company working to change what is possible for people living with T cell-driven autoimmune diseases, announced it is leveraging its validated T cell-directed lipid nanoparticle (ctLNP) to develop siRNA therapeutics

      1/6/25 4:30:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results

      Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) Cash balance of $199.8 million expected to fund operations into 2H 2027 CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2024 financial results. "There is immense potential for a new class of redosable, selectively targeted in vivo genetic medicines to fulfill the needs of people living with diseases that remain unaddressed by existing treatment options," said Geoff

      11/6/24 4:05:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress

      New non-human primate data show highly selective in vivo delivery of mRNA to T cells with a cell-targeted lipid nanoparticle (ctLNP) CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented data on its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress. The company presented data showing that a single IV dose of its ctLNP delivered mRNA encoding a reporter protein to a majority of circulating T cells in non-human primates (NHPs). In the

      10/22/24 6:59:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio to Present at the 2024 Cantor Global Healthcare Conference

      CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 10:20 a.m. ET in New York. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation Bio    Generation Bio is innovating non-viral genetic medicines

      9/12/24 4:05:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Reports Second Quarter 2024 Financial Results

      CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2024 financial results. "We continue to apply our proprietary cell-targeted LNP delivery system to develop in vivo genetic medicines for T cells, hematopoietic stem cells and hepatocytes," said Geoff McDonough, chief executive officer of Generation Bio. "We believe our delivery platform has the potential to create uniquely differentiated in vivo therapeutics that are redosable, delivered at point-of-care, and scalable at low cost, thereby addressing chal

      8/7/24 4:05:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Generation Bio Co. Leadership Updates

    Live Leadership Updates

    See more
    • Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

      Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it

      2/6/25 5:00:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

      Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent disea

      5/10/23 4:15:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

      CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary. "We are delighted to welcome Yalonda to the Generation Bio leadership team and look forward to drawing on her extensive legal expertise as we continue to execute on our vision of reaching the full potential of genetic medicine," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "Generation Bio is pursuing an ambitious goal to develop lifelong, titratable gain of function DNA th

      4/5/23 7:30:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results

      CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results. "We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progress in establishing the proprietary technologies necessary to realize our vision," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "This quarter, process development and scaling of rapid enzymatic synthesis (RES) for prod

      8/4/22 4:15:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Appoints Dannielle Appelhans to Its Board of Directors

      CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Dannielle Appelhans has been appointed to its Board of Directors. Dannielle Appelhans is a tenured pharmaceutical executive who has built deep expertise in strategy, manufacturing, supply chain and operations. She is currently the Chief Operating Officer of Rubius Therapeutics, where she oversees Corporate Strategy, Communications, Quality, Technical Development and Operations. Prior to joining Rubius, Appelhans held multiple executive-level positions at Novartis, including Global

      7/18/22 7:30:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer

      Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Dr. Patrik De Haes, who after 14 years as CEO, has decided to move away from day-to-day management of the company to become the Non-executive Chairman of Oxurion. Thomas Clay, the outgoing Chairman of Oxurion, will remain

      5/17/21 1:30:00 AM ET
      $VRTX
      $IRWD
      $GBIO
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Appoints Ron Cooper to Its Board of Directors

      CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has been appointed to its Board of Directors. The appointment is effective March 1, 2021. Ron Cooper is a global biopharmaceutical executive who currently serves as president, chief executive officer and board member of Albireo Pharma, Inc., a position he has held since June 2015. He has successfully matured Albireo Pharma, Inc. to a clinical-stage public company on the verge of its first drug approval. Prior to joining Albireo Pharma, Inc., Cooper had a 25-year career at Bristol Myers Squibb, d

      2/18/21 7:30:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care